HC Wainwright Brokers Increase Earnings Estimates for Omeros

Omeros Corporation (NASDAQ:OMER) – HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Omeros in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will earn ($0.40) per share for the quarter, up from their prior estimate of ($0.59). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at ($0.08) EPS, FY2028 earnings at $2.05 EPS, FY2029 earnings at $4.06 EPS and FY2030 earnings at $5.23 EPS.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, topping the consensus estimate of ($0.55) by $3.69.

A number of other research firms have also recently commented on OMER. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Omeros Stock Down 9.8%

Shares of NASDAQ:OMER opened at $10.90 on Friday. The company has a market capitalization of $784.80 million, a P/E ratio of -21.80 and a beta of 2.53. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The stock’s fifty day simple moving average is $11.38 and its 200-day simple moving average is $9.78.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omeros

Large investors have recently added to or reduced their stakes in the business. UBS Group AG grew its holdings in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares during the period. Vanguard Group Inc. increased its stake in shares of Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after acquiring an additional 666,357 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Omeros by 1,201.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after acquiring an additional 384,168 shares during the period. State Street Corp lifted its holdings in shares of Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after acquiring an additional 333,798 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after acquiring an additional 263,095 shares during the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results beat expectations driven by a one‑time Novo Nordisk deal that materially lifted EPS; investors have been upbeat about the earnings surprise and the deal’s cash impact. Omeros Corporation Q4 2025 Earnings Call Summary
• Positive Sentiment: Management says YARTEMLEA is expected to be financially self‑sustaining in 2026 and the company is targeting positive cash flow in 2027 — a clear longer‑term de‑risking catalyst if execution continues. Omeros expects YARTEMLEA to be financially self-sustaining in 2026…
• Positive Sentiment: Unusually large call‑option buying was reported ahead of and around the earnings period, suggesting some traders expect further upside or continued volatility. (Market options flow reported 7,487 calls bought vs a typical ~4,876.)
• Neutral Sentiment: Full earnings‑call transcripts and summaries provide operational context (deal terms, launch timelines, FDA updates) but contain mixed detail; these are useful for assessing whether recent gains are sustainable. Earnings Call Transcript
• Neutral Sentiment: Analyst pieces and bullish case writeups frame a potential upside ahead of Q1 commercial updates, but they also note execution and commercialization milestones that must be met. Making The Bull Case On Q4 Earnings
• Negative Sentiment: Some analyst commentary was mixed, highlighting that the EPS beat was boosted by a one‑time windfall and that forward commercial execution and sustainable revenue proof points will determine longer‑term valuation — potentially tempering enthusiasm. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: After a post‑earnings after‑hours pop tied to the Novo deal and launch optimism, some investors appear to be taking profits or reassessing valuation, which likely contributed to intraday selling pressure. OMER stock surges 5% after-hours

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.